Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN

Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN

191
Other
Proteomics
Breast and Gynecologic Cancers Research

This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers. The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer. These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory. In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis. Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins. Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.

Our specific aims are to: 1)   Perform two comprehensive proteomic profiling experiments. a.   Diagnosed between two years and four months before diagnosis. b.   Diagnosed between four years and two years before diagnosis. 2)   Analyze and disseminate the raw and processed data. a.   Search data from pre-clinical specimens and combine with results from clinical specimens. b.   Stage and disseminate data on queryable system and make available to EDRN. 3)   Provide MS/MS data analysis and interpretation support to the EDRN, and cooperation with the DMCC. a.   Provide consulting with researchers who wish to interpret the resulting ovarian data. b.   Process and stage other MS/MS proteomic data identified by the EDRN for dissemination through the network and under the supervision of the DMCC.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.